Slide 1: Second quarter and first half 2026 financial results
JULY 30, 2026 Second quarter and first NASDAQ: PHAR half 2026 financial results EURONEXT Amsterdam: PHARM 1
Slide 2: Introduction
CEO Fabrice Chouraqui Chief Executive Officer Introduction 2
Slide 3: Speakers
Speakers Fabrice Chouraqui Leverne Marsh Anurag Relan, MD Kenneth Lynard Chief Executive Officer Chief Commercial Officer Chief Medical Officer Chief Financial Officer 3
Slide 4: Forward-looking statements
Forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual resu
Slide 5: Strong commercial foundation with high-value pipeline
Strong commercial foundation with high-value pipeline HAE PIDs PMD Hereditary Angioedema Primary Immunodeficiencies Primary Mitochondrial with immune dysregulation Disease RUCONEST® Joenja® (leniolisib) napazimone (KL1333) APPROVED for acute HAE APPROVED for APDS CLINICAL • Cornerstone on-demand • A
Slide 6: Q2 2026 updates
Q2 2026 updates Revenues RUCONEST resilience • Patient base 93% of year-ago level RUCONEST Joenja • Renewed strength in new enrollments • New prescriber additions Amounts in US$ million -3% 93.2 90.2 12.8 Joenja growth momentum 17.9 • 40% revenue growth in APDS • Geographic expansion accelerating 80
Slide 7: Key near-term milestones
Key near-term milestones Revenues expected to stabilize RUCONEST for HAE with return to growth during 2H 2026 Geographic expansion Joenja for APDS Pediatric label expansion (U.S.) Joenja (leniolisib) Two Phase II trial readouts for the broader for additional PIDs CVID patient population 7
Slide 8: Commercial update
CCO Leverne Marsh Chief Commercial Officer Commercial update 8
Slide 9: RUCONEST Q2 performance
RUCONEST Q2 performance Improvement in Financial performance Resilient patient base underlying demand Revenue: $72.3M 84 new patient Dyn amic Patients -10% vs. Q2 2025 enrollments Active +24% vs. Q1 2026 RUCONEST New Starts Patients Switches Restarts Drop Offs Stabilization with return to 93% revenu
Slide 10: RUCONEST – durable market position in high-burden HAE
RUCONEST – durable market position in high-burden HAE Differentiated value proposition • Targets the root cause of HAE across all pathways • Efficacy and reliability of IV self administration Overwhelming majority of Mostly used by patients experiencing more RUCONEST patients remain severe / frequen
Slide 11: RUCONEST – rapid, reliable, complete attack resolution
RUCONEST – rapid, reliable, complete attack resolution Stopped 97% of acute attacks 93% Median time to complete attack needed just one dose of attacks for at resolution with of RUCONEST1 least 3 days2 RUCONEST3 1 3 4.5 DOSE DAYS HOURS References: 1. RUCONEST. Prescribing information. Pharming Health
Slide 12: Joenja Q2 update – strong global momentum in APDS
Joenja Q2 update – strong global momentum in APDS ahead of geographic and pediatric expansion expected this year Joenja revenue (global) U.S. patients on Joenja U.S. EU & RoW 132 Revenue +40% 127 17.9 120 114 116 132 patients on therapy in US Amounts in US$ million 2.5 12.8 +150% 102 (+16% vs 2Q25)
Slide 13: Joenja expansion from APDS foundation into broad blockbuster immunology opportunity
Joenja expansion from APDS foundation into broad blockbuster immunology opportunity Broad PIDs/CVID Opportunity*** International APDS Expansion • Genetic PIDs with U.S. APDS immune dysregulation Expansion • Focused geo- (>2,500 U.S. patients) Established APDS expansion that Commercial Base • Pediatr
Slide 14: R&D update
CMO Anurag Relan Chief Medical Officer R&D update 14
Slide 15: PI3Kδ is a master regulator of the immune system
PI3Kẟ is a master regulator of the immune system and imbalance contributes to immune dysregulation PI3Kẟ is a master regulator of the Immune dysregulation pathology immune system Lymphoproliferation p110δ PI3Kδ p85ɑ AKT/PKB Autoimmunity FOXO mTOR GI Disease Cell trafficking Cell Growth Cell prolifer
Slide 16: PI3Kδ inhibition validated in APDS
PI3Kδ inhibition validated in APDS Sustained, durable efficacy Lymph-node and spleen volume reduced, sustained through multi-year OLE† Joenja (leniolisib) Established safety and tolerability* APPROVED for APDS Primarily mild-to-moderate adverse events; no treatment- related SAEs with up to 7 years o
Slide 17: Leniolisib opportunity across primary immunodeficiencies
Leniolisib opportunity: Targeting shared PI3Kδ-driven immune dysregulation across primary immunodeficiencies (PIDs) Two Phase II trials Genetic PIDs with immune dysregulation APPROVED Joenja (leniolisib) Expanding the addressable market linked to PI3Kẟ APDS CVID with immune dysregulation Shared clin
Slide 18: Leniolisib Phase II trials in CVID and PIDs: fully enrolled, readouts 4Q 2026
Leniolisib Phase II trials in CVID and PIDs: Fully 5 enrolled, readouts 4Q 2026 CVID with immune dysregulation N = 20 Genetic PIDs with immune dysregulation N = 12 Open-label, single-arm, multi-center Open-label, single-arm basket trial at NIH (ALPS-FAS, CTLA4, NFKB1, PTEN, SOCS1, NRAS/KRAS RALD) NC
Slide 19: Financial results and outlook
CFO Kenneth Lynard Chief Financial Officer Financial results and outlook 19
Slide 20: Financial highlights: Q2 2026 vs Q2 2025
Financial highlights: Q2 2026 vs Q2 2025 Revenues Adjusted (Non-GAAP) Operating Cash flow from operations RUCONEST Joenja profit (loss)* Amounts in US$ million Amounts in US$ million Amounts in US$ million 12.9 11.7 93.2 90.2 7.9 12.8 -3% 17.9 80.4 72.3 (9.7) Q2 2025 Q2 2026 Q2 2025 Q2 2026 Q2 2025
Slide 21: Financial highlights: H1 2026 vs H1 2025
Financial highlights: H1 2026 vs H1 2025 Revenues Adjusted (Non-GAAP) Operating Cash flow from operations RUCONEST Joenja profit (loss)* 172.3 162.7 Amounts in US$ million Amounts in US$ million Amounts in US$ million 13.7 23.3 12.0 32.0 -6% 3.0 149.0 130.7 (7.7) H1 2025 H1 2026 H1 2025 H1 2026 H1 2
Slide 22: 2026 financial guidance and long-term capital outlook
2026 financial guidance and long-term capital outlook Revenue and operating expenses (in constant currency): FY 2026 Guidance Notes Total Revenues US$375 - 395 million • 0 - 5% growth • 1 – 3% growth • +US$40 million R&D to advance pipeline Operating Expenses US$315 - 320 million • -US$9 million fro
Slide 23: Conclusion
CEO Fabrice Chouraqui Chief Executive Officer Conclusion 23
Slide 24: Updated 2026 outlook with solid fundamentals and near-term clinical catalysts
Updated 2026 outlook with solid fundamentals and compelling near-term clinical catalysts Significant growth Building a leading rare Q2 updates/overview opportunities disease company Joenja - commercial • Lowered Revenue guidance to • Geographic, pediatric and • More disciplined operating model US$37
Slide 25: Q&A
Q&A Fabrice Chouraqui Leverne Marsh Anurag Relan, MD Kenneth Lynard Chief Executive Officer Chief Commercial Officer Chief Medical Officer Chief Financial Officer 25
Slide 26: Thank you!
WWW.PHARMING.COM The Netherlands Pharming Group Thank you! Vondellaan 47 2332 AA Leiden The Netherlands United States Pharming Healthcare, Inc. 10 Independence Blvd Suite 401, Joenja® and RUCONEST® are registered trademarks owned by or licensed to Pharming Group N.V. Warren or its affiliates. Other
Slide 27: Appendix
27 Appendix @ Pharming’
Slide 28: Statement of profit and loss
Statement of profit and loss 28
Slide 29: Balance sheet – assets
Balance sheet -— assets Guine)30)2026) December 31, 2025 Inventories 14 65,428 64,902 Non-current assets Intangible assets 128,082 135,538 Property, plant and equipment 6,425 7,233 Right-of-use assets 14,058 16,738 Long-term prepayments 92 94 Deferred tax assets B 28,838 31,017 Investment accounted
Slide 30: Balance sheet – liabilities
Balance sheet – liabilities 30
Slide 31: Cash flow (1/2)
Cash flow (1/2) 1 Comparative presentation updated for consistency. 31
Slide 32: Cash flow (2/2)
Cash flow (2/2) 32 [Capital expenditure for property, plant and equipment (321) (410) Investment intangible assets = (6) Investment in associates using the equity method = (429) Purchases of marketable securities (102,646) = Proceeds from sale of marketable securities 18,124 84,967 [Acquisition of a